The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome

Abstract

In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.

Serum paraoxonase‐1 activity is inversely related to free thyroxine in euthyroid subjects: The PREVEND Cohort Study

“…Further, PON‐1 activity was elevated in women who used oral contraceptives. Although little information is available on this issue, it seems consistent with some other data suggesting that PON‐1 activity is higher in women taking oral contraceptives and may increase in response to ethinyl oestradiol and cyproterone acetate combination …”

“…TSH is logarithmically transformed some other data suggesting that PON-1 activity is higher in women taking oral contraceptives and may increase in response to ethinyl oestradiol and cyproterone acetate combination. 58,59 Several other methodological aspects and limitations of our study need to be considered. We performed a crosssectional study, so that conclusions regarding cause-effect relationships cannot be drawn with certainty.…”

The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome

“…According to the National Cholesterol Education Program guidelines, about 70% of women with PCOS have borderline or high lipid concentrations (Legro et al, 2001). In addition, few studies have reported that oxidized low-density lipoprotein (Ox-LDL) levels as a marker of altered lipid metabolism were significantly higher in untreated PCOS patients than controls (Macut et al, 2006;Carlioglu et al, 2014). Elevated levels of Ox-LDL are associated with the initiation and progression of atherosclerosis (Ehara et al, 2001).…”

PON1 polymorphisms are associated with polycystic ovary syndrome susceptibility, related traits, and PON1 activity in Indian women with the syndrome

“…A few groups of investigators have also explored the relationship of these polymorphisms with PCOS and its related traits (23)(24)(25)(26). Treatment with metformin and hormonal supplements (ethinyloestradiol þ cyproterone acetate) has been shown to increase PON1 activity and subsequently decrease oxidative stress in women with PCOS (27,28). However, to our knowledge, no conclusive study exploring the association of PON1 polymorphisms and its activity with PCOS risk, and their relationship with cardiovascular and metabolic dysfunction is available.…”